Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous umbilical cord blood mononuclear cells
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous umbilical cord blood mononuclear cells is an investigational cell therapy developed by The University of Texas Health Science Center at Houston (UTHealth Houston) for the treatment of hypoxic neurologic injury in infants with high-risk congenital diaphragmatic hernia (CDH). The therapy consists of mononuclear cells isolated from the patient's own umbilical cord blood collected at birth. It is administered intravenously in four doses over the first week of life. These cells are hypothesized to mitigate brain injury by modulating the inflammatory response and promoting neuroprotection and repair mechanisms. This biologic therapy is currently being evaluated in a Phase 1 clinical trial at Children's Memorial Hermann Hospital to determine its safety and potential to improve neurological and neurodevelopmental outcomes in this high-risk population, which currently lacks approved neuroprotective treatments.
- Other names
- autologous umbilical cord bloodautologous UCB mononuclear cells
Beyond the preview
Go deeper on autologous umbilical cord blood mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous umbilical cord blood mononuclear cells.